Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Low Dose Mosunetuzumab for Indolent B-Cell Lymphoma

NCT06442475 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT06442475
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06442475 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Low Dose Mosunetuzumab for Indolent B-Cell Lymphoma
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Recruiting
Start date
August 29, 2024
Completion date
February 12, 2028
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ann arbor stage ii follicular lymphoma, ann arbor stage ii marginal zone lymphoma, ann arbor stage iii follicular lymphoma, ann arbor stage iii marginal zone lymphoma, ann arbor stage iv follicular lymphoma, ann arbor stage iv marginal zone lymphoma, grade 1 follicular lymphoma, grade 2 follicular lymphoma, grade 3a follicular lymphoma